Evidence map›Paper›PMID 41653358›Full record

ReviewCurrent oncology reports2026

Utilization of Steroid Sparing Agents for Immune-Related Adverse Events (irAEs): Management Strategies and Considerations.

Sherin J Rouhani, Matthew J Hadfield, Matthew Lei, Ross D Merkin, Michael Dougan, Gabriela S Hobbs, Sarah P Hammond, Kerry L Reynolds

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sherin J Rouhani *Mass General Brigham Cancer Institute, Massachusetts General Hospital, 55 Fruit Street Bartlett Hall, Room 202, Boston, MA, 02114, USA.
Matthew J Hadfield *Division of Hematology Oncology, Department of Medicine, Brown University Health, Providence, RI, USA.
Matthew LeiMass General Brigham Cancer Institute, Massachusetts General Hospital, 55 Fruit Street Bartlett Hall, Room 202, Boston, MA, 02114, USA.
Ross D MerkinMass General Brigham Cancer Institute, Massachusetts General Hospital, 55 Fruit Street Bartlett Hall, Room 202, Boston, MA, 02114, USA.
Michael DouganHarvard Medical School, Boston, MA, USA.
Gabriela S HobbsMass General Brigham Cancer Institute, Massachusetts General Hospital, 55 Fruit Street Bartlett Hall, Room 202, Boston, MA, 02114, USA.
Sarah P HammondMass General Brigham Cancer Institute, Massachusetts General Hospital, 55 Fruit Street Bartlett Hall, Room 202, Boston, MA, 02114, USA.
Kerry L ReynoldsMass General Brigham Cancer Institute, Massachusetts General Hospital, 55 Fruit Street Bartlett Hall, Room 202, Boston, MA, 02114, USA. Kreynolds7@mgb.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewSteroid-sparing immunomodulatory agents (SSIAs) are frequently used to treat steroid-refractory immune related adverse events (irAEs) from immune checkpoint inhibitors (ICIs). This paper aims to review the evidence supporting the use of particular SSIAs for different irAEs, and practical considerations for choosing between SSIAs including unique toxicity profiles, infectious considerations, and cost implications. RECENT

findingsSSIAs have been shown to be effective for steroid-refractory irAEs in multiple case series and some clinical trials, but there is limited prospective evidence comparing the efficacy of one SSIA to another. Effective treatment of irAEs is essential to improving patient outcomes. This article aims to help clinicians understand the data behind available SSIAs, and understand drug-specific considerations that may influence the choice of SSIAs in different situations.

Indexed as

Drug-Related Side Effects and Adverse ReactionsImmune Checkpoint InhibitorsImmunomodulating AgentsImmunotherapyNeoplasmsSteroidsHumansImmune Checkpoint InhibitorsImmunomodulating AgentsSteroidsImmune checkpoint inhibitorsImmune-related adverse eventsImmunotherapy toxicitySteroid-sparing immunomodulatory agents

Identifiers

PMID41653358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.